C. Karagiannidis (Cologne, Germany), I. Martin-Loeches (Dublin, Ireland)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
This session includes the Best Abstract for Assembly 2 - Respiratory Intensive Care, entitled "Association between PEEP and VFD in COVID–19 ARDS”
Use of low tidal volume ventilation (LTVV) has an association with outcome in COVID-19 patients
S. Nijbroek (Amsterdam, Netherlands), D. Ivanov (Amsterdam, Netherlands), L. Hol (Amsterdam, Netherlands), M. Hollmann (Amsterdam, Netherlands), A. Serpa Neto (Melbourne, Australia), M. Schultz (Amsterdam, Netherlands), F. Paulus (Amsterdam, Netherlands)
|    |
Association between PEEP and VFD in COVID–19 ARDS
C. Valk (Amsterdam, Netherlands), A. Tsonas (Amsterdam, Netherlands), M. Botta (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands), J. Pillay (Groningen, Netherlands), A. Serpa Neto (Melbourne, Australia), M. Schultz (Amsterdam, Netherlands), F. Paulus (Amsterdam, Netherlands)
| |
Use of neuromuscular blocking agents in mechanically ventilated patients with COVID-19: A propensity score analysis
G. Li Bassi (Chermside, Australia), K. Gibbons (Brisbane, Australia), J. Suen (Chermside, Australia), H. Dalton (Falls Church, United States of America), N. White (Brisbane, Australia), A. Corley (Chermside, Australia), S. Hinton (Chermside, Australia), S. Forsyth (Brisbane, Australia), J. Laffey (Galway, Australia), D. Brodie (NY, United States of America), A. Burrell (Melbourne, Australia), E. Fan (Toronto, Canada), R. Bartlett (Ann Arbor, United States of America), A. Torres (Barcelona, Spain), D. Chiumello (Milan, Italy), A. Elhazmi (Riyadh, Saudi Arabia), C. Hodgson (Melbourne, Australia), S. Ichiba (Tokyo, Japan), C. Luna (Buenos Aires, Argentina), S. Murthy (Vancouver, Canada), A. Nichol (Dublin, Ireland), P. Ng (Hong Kong, China), M. Panigada (Milan, Italy), J. Fraser (Chermside, Australia)
| |
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 from CIBERESUCICOVID study
A. Torres (Barcelona, Spain)
| |
Impaired ventilation is not independently associated with 28-day mortality in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS)
L. Morales Quinteros (Sabadell, Spain), A. Serpa Neto (Melbourne, Australia), A. Artigas (Sabadell, Spain), L. Blanch (Sabadell, Spain), M. Botta (Amsterdam, Netherlands), D. Kaufman (New Yor, United States of America), M. Schultz (Amsterdam, Netherlands), A. Tsonas (Amsterdam, Netherlands), F. Paulus (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands)
| |
Associations of BMI with ventilation management and outcomes in COVID-19 ARDS patients
M. Schultz (Amsterdam, Netherlands), R. Schavemaker (Amsterdam, Netherlands), W. Lagrand (Amsterdam, Netherlands), E. Van Slobbe–bijlsma (Hilversum, Netherlands), A. Serpa Neto (Melbourne, Australia), F. Paulus (Amsterdam, Netherlands)
| |
Prone positioning in patients with COVID-19 under invasive mechanical ventilation and acute respiratory distress syndrome: a multicenter cohort study
M. Cunha (Sao Paulo, Brazil), R. Plentz (Porto Alegre, Brazil), G. Sant'Anna (Sao Paulo, Brazil), A. Lunardi (Sao Paulo, Brazil), L. Isensee (Sao Paulo, Brazil), R. Xavier (Sao Paulo, Brazil), J. Schardong (Porto Alegre, Brazil), N. Righi (Porto Alegre, Brazil), J. Ferreira (Sao Paulo, Brazil), C. Carvalho (Sao Paulo, Brazil)
| |
Effect of fully-automated vs conventional ventilation on mechanical power of ventilation in COVID–19 ARDS patients
L. Buiteman-Kruizinga (Delft, Netherlands), H. Mkadmi (Delft, Netherlands), A. Serpa Neto (Melbourne, Australia), M. Botta (Amsterdam, Netherlands), M. Schultz (Amsterdam, Netherlands), F. Paulus (Amsterdam, Netherlands), P. Van Der Heiden (Delft, Netherlands)
| |
Late Breaking Abstract - Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO
P. Vizcarra (Madrid, Spain), M. Sanchez (Madrid, Spain), J. Pérez-García (Barcelona, Spain), M. Gion (Madrid, Spain), M. Martialay (Madrid, Spain), J. Taboada (Madrid, Spain), S. De La Torre (Madrid, Spain), M. Sampayo-Cordero (Barcelona, Spain), A. Malfettone (Barcelona, Spain), A. Llombart-Cussac (Valencia, Spain), J. Cortés (Barcelona, Spain)
| |